Proteasome Inhibitors: Potential in Rheumatoid Arthritis Therapy?
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26072943 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Oktávia Tarjányi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biology, Medical School, University of Pecs, H-7624 Pecs, Hungary. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Proteasome Inhibitors, Antirheumatic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Culture and Innovation of Hungary from the National Research, Development and In-novation Fund, Ministry of Culture and Innovation of Hungary from the National Research, Development and Innovation Fund.
Abstract (Originalsprache)
Rheumatoid arthritis (RA) is a chronic autoimmune disease that leads to the destruction of peripheral joint cartilage and bone tissue. Despite the advent of biological therapies in the past decades, the complete remission of RA patients is still out of reach. Therefore, the search for novel therapeutic approaches is still open in the field of RA. Proteasome inhibitors (PIs) were originally designed to be used in hematological malignancies like multiple myeloma. However, evidence has shown that they are potent inhibitors of the NF-κB pathway, which plays a pivotal role in inflammatory processes and RA. Furthermore, inhibition of cell activation and induction of apoptosis was also reported about PIs. In the present review, we summarize the current knowledge about the potential effects of PIs in RA based on reports from animal and human studies. We believe that there is substantial potential in the use of PIs in RA therapy either alone or in combination with the medications already used.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biology, Medical School, University of Pecs, H-7624 Pecs, Hungary.
- Department of Immunology and Biotechnology, Medical School, University of Pecs, H-7624 Pecs, Hungary.
ORCID-Profile: Oktávia Tarjányi, György Sétáló, Ferenc Boldizsár
Förderung
- Ministry of Culture and Innovation of Hungary from the National Research, Development and In-novation Fund
- Ministry of Culture and Innovation of Hungary from the National Research, Development and Innovation Fund
Zitieren
APA
Tarjányi, O., Olasz, K., Rátky, F., Sétáló, G., & Boldizsár, F. (2025). Proteasome Inhibitors: Potential in Rheumatoid Arthritis Therapy?. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26072943
Vancouver
Tarjányi O, Olasz K, Rátky F, Sétáló G, Boldizsár F. Proteasome Inhibitors: Potential in Rheumatoid Arthritis Therapy?. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26072943
BibTeX
@article{Tarjnyi2025,
author = {Tarjányi, Oktávia and Olasz, Katalin and Rátky, Fanni and Sétáló, György and Boldizsár, Ferenc},
title = {Proteasome Inhibitors: Potential in Rheumatoid Arthritis Therapy?},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26072943}
}
EUVIMED